Gastrolaryn® Stick Following Proton Pump Inhibitor Treatment in Patients with Gastroesophageal Reflux Disease: A Multicenter Real-World Observational Survey
- 1Medicine and Healthcare Science Department, University of Molise, 86100 Campobasso, Italy
- 2Department of Otorhinolaryngology, University Kore, 94100 Enna, Italy
Abstract
Background: Symptom management after proton pump inhibitor (PPI) treatment remains an important issue in gastroesophageal reflux disease (GERD). Objective: To describe symptom distributions during a sequential PPI and Gastrolaryn® Stick management pathway in routine outpatient practice. Methods: In a multicenter, prospective observational survey, 263 GERD patient records were collected at baseline (T0) by 17 gastroenterologists. The intended management sequence comprised 8 weeks of esomeprazole 40 mg daily (T0–T1) followed by 8 weeks of Gastrolaryn® Stick (one stick twice daily; T1–T2). Outcomes included GERD Impact Scale (GIS) response distributions and routine-care characteristics. Analyses were descriptive and based on available records at each survey timepoint. Results: Records were available for 124 patients at T1 (47.1% of baseline) and 112 at T2 (42.6%). Across recorded GIS item responses, the proportion rated “every day” was 12.8%, 0.9%, and 0.3% at T0, T1, and T2, respectively; the corresponding “never” proportions were 24.8%, 44.5%, and 58.4%. These are unpaired, timepoint-specific descriptive summaries and do not establish individual improvement. Investigators submitting records declined from 17 to 11 and 7. Conclusions: Among available records, symptom-frequency distributions were more favorable at later survey timepoints. Substantial missing follow-up, changing site participation, the lack of a comparator and unavailable patient-level paired analyses prevent causal attribution, assessment of relapse prevention, or definitive conclusions about maintenance effectiveness. The survey nevertheless documents management and follow-up patterns encountered in routine practice.
Related
- Umbrella review of meta-analyses: perioperative immune checkpoint inhibitor therapy in resectable gastric and gastroesophageal junction adenocarcinoma
- Upstaging of Operable Adenocarcinoma of the Stomach and Gastroesophageal Junction Following Staging Laparoscopy (SL): High-Risk Clinicopathological Features Requisite for Mandatory SL
- Effectiveness and Patient Compliance of a Needle-Free Injection System in Controlled Ovarian Stimulation in IVF Cycles: A Real-World, Investigator-Initiated, Retrospective, Multicenter, Observational Study
- Incisional hernia prevention in high-risk midline laparotomy using onlay PVDF mesh: multicenter prospective observational study
- Evaluation of early C‐reactive protein kinetics as an early response marker in biliary tract cancer treated with combined chemoimmunotherapy: A multicenter observational study
BibTeX
@article{ciprandi2026gastrolaryn,
title = {{Gastrolaryn® Stick Following Proton Pump Inhibitor Treatment in Patients with Gastroesophageal Reflux Disease: A Multicenter Real-World Observational Survey}},
author = {Giorgio Ciprandi and Ignazio La Mantia and Attilio Varricchio},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15218516},
url = {https://www.mdpi.com/2077-0383/15/21/8516},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Gastrolaryn® Stick Following Proton Pump Inhibitor Treatment in Patients with Gastroesophageal Reflux Disease: A Multicenter Real-World Observational Survey
AU - Giorgio Ciprandi
AU - Ignazio La Mantia
AU - Attilio Varricchio
PY - 2026
DA - 2026/11/02
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218516
UR - https://www.mdpi.com/2077-0383/15/21/8516
AB - Background: Symptom management after proton pump inhibitor (PPI) treatment remains an important issue in gastroesophageal reflux disease (GERD). Objective: To describe symptom distributions during a sequential PPI and Gastrolaryn® Stick management pathway in routine outpatient practice. Methods: In a multicenter, prospective observational survey, 263 GERD patient records were collected at baseline (T0) by 17 gastroenterologists. The intended management sequence comprised 8 weeks of esomeprazole 40 mg daily (T0–T1) followed by 8 weeks of Gastrolaryn® Stick (one stick twice daily; T1–T2). Outcomes included GERD Impact Scale (GIS) response distributions and routine-care characteristics. Analyses were descriptive and based on available records at each survey timepoint. Results: Records were available for 124 patients at T1 (47.1% of baseline) and 112 at T2 (42.6%). Across recorded GIS item responses, the proportion rated “every day” was 12.8%, 0.9%, and 0.3% at T0, T1, and T2, respectively; the corresponding “never” proportions were 24.8%, 44.5%, and 58.4%. These are unpaired, timepoint-specific descriptive summaries and do not establish individual improvement. Investigators submitting records declined from 17 to 11 and 7. Conclusions: Among available records, symptom-frequency distributions were more favorable at later survey timepoints. Substantial missing follow-up, changing site participation, the lack of a comparator and unavailable patient-level paired analyses prevent causal attribution, assessment of relapse prevention, or definitive conclusions about maintenance effectiveness. The survey nevertheless documents management and follow-up patterns encountered in routine practice.
SN - 2077-0383
ER -